Coherus Will Not Alert Filing Of Pegfilgrastim On-Body
Approval Or Launch Will Trigger Notification To Market
Executive Summary
Going toe-to-toe with Amgen on its Neulasta Onpro on-body injector device is a key strategic goal for Coherus BioSciences, although news will be kept concealed until the company’s proposed biosimilar is approved or launched.
You may also be interested in...
Apobiologix Launches Pegfilgrastim Autoinjector In Canada
Apobiologix’s new Lapelga autoinjector that the firm has just introduced in Canada is only the second on-body pegfilgrastim device to launch after Amgen’s Neulasta original.
Coherus Aims To Pull Out $75m In Costs Amid Conservative 2023 Guidance
Coherus BioSciences saw its Q3 revenues tumble by 45% as it arrived at the firm’s projected nadir. A swathe of launches and a cost-cutting program are targeted to bring the firm back to profitability in 2024.
Coherus Reveals US Launch Plans For Interchangeable Ranibizumab
Coherus has revealed further details of the firm’s plans for its Cimerli interchangeable biosimilar rival to Lucentis in the US, including a launch date and pricing information.